7 VC firms investing in healthcare & digital health and agetech & longevity at the Series A stage.
F4 Fund tracks 7 VC firms that actively invest in healthcare & digital health + agetech & longevity at the Series A stage, with check sizes ranging from $100K – $8M (median: $1.6M – $1.6M). As of June 2026, and 86% lead or co-lead rounds. Rankings are based on F4's proprietary analysis of 1,356+ researched VC firms, scored by data completeness, portfolio depth, investment recency, and stage alignment.
| # | Firm | Check Size | Portfolio | Leads? | Activity | Decision | Intro |
|---|---|---|---|---|---|---|---|
| 1 | ▶ Primetime Partners The longevity economy is a massive addressable market. Companies transforming quality of life for aging adults will be highly profitable and impactful. Experienced founders over 50 solve aging problems better because they understand them firsthand. New York | $250K – $1M | 14 | Leads | Active | ~1 mo | Open |
| 2 | ▶ Equitage Ventures Backs early-stage AgeTech, senior-care, digital-health, and technology-enabled services companies transforming the aging journey, using a senior-care operator and LP network to help with distribution, diligence, product feedback, talent, and go-to-market. Denver | $250K – $2.5M | 23 | — | Active | ~1 mo | Open |
| 3 | ▶ The Longevity Fund Longevity is a completely new industry within biotech requiring founders who can think differently. Mission-oriented, founder-led companies with unconventional backgrounds will prove most effective at bringing the first longevity drugs to market and extending human healthy lifespan. The field is at a critical inflection point where we will either breakthrough to mainstream or get silo'd in a funding winter. San Francisco | $250K – $3M | 23 | Leads | Active | ~2 wks | Open |
| 4 | ▶ AGE1 Funding the next generation of contrarian founders building breakthrough longevity biotech companies. We invest in the transition from sickcare to healthcare by extending healthy lifespan and preventing age-related disease. | $500K – $4M | 20 | Leads | Active | — | — |
| 5 | ▶ Kalos Ventures Kalos backs founders building at the intersection of AI/automation/robotics and rapid demographic change — specifically in workforce, care, and education. They seek founders with unique market experience and systems-level thinking who can drive structural change in undercapitalized but critical sectors. New York | $1M – $8M | 9 | Leads | Active | ~2 mo | — |
| 6 | ▶ The Helm Women receive only 2% of venture capital despite female-founded startups delivering 2x return per dollar vs. all-male teams. The Helm invests in game-changing, undervalued companies at seed stage founded by women, providing not just capital but operational support and ecosystem access. New York | $250K – $1.5M | 26 | Leads | Active | ~2 wks | Open |
| 7 | ▶ Concrete Rose Capital We invest financial and social capital into exceptional ventures led by visionary, values-aligned teams. Technology is the 'new West' - we seek to broaden opportunities by partnering with pioneering founders to bring entire communities along on their journey of reimagining the world. San Francisco | $100K – $5M | 47 | Both | Active | ~2 mo | Open |
What other stages do these firms also invest in?
Investors on this page also frequently invest in these sectors
What other sectors do these firms also invest in?
F4 Fund tracks 7 VC firms that actively invest in healthcare & digital health + agetech & longevity at the Series A stage. These firms are ranked using a composite score that weighs data completeness (30%), portfolio depth (30%), investment recency (25%), and stage alignment (15%).
Based on F4's analysis, the median check size for series a healthcare & digital health + agetech & longevity investors is $1.6M – $1.6M, with a full range from $100K – $8M. The distribution breaks down as: 2 firms in the $500K-$1M range, 2 firms in the $1M-$2M range, 3 firms in the $2M-$5M range.
Among the 7 firms tracked, 86% lead or co-lead rounds. Founders seeking a lead investor should filter for firms marked "Leads" or "Both" in the rankings table above. Lead investors typically set deal terms and anchor the round.
The best series a healthcare & digital health + agetech & longevity investors combine domain expertise with an active portfolio in the space. Among these firms, 0% prefer warm introductions, and the average firm has 23 portfolio companies. Look for firms whose check size matches your raise, whose stage preference aligns with yours, and who have a track record of supporting companies in your sector through multiple growth phases.
Firm profiles are continuously updated through F4's research pipeline, which combines LLM-powered web research, portfolio analysis, and transcript extraction. The ranking data refreshes every 12 hours. Editorial analysis is reviewed weekly. Individual firm profiles are re-researched on a 30-day cycle or when new information surfaces.